Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 3/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31630067 | 0.89 | PARP1 (0.37) | HTR2AHTR2CHTR2BKDM1AKCNH2 | |
| SCHEMBL1142545 | 0.81 | CTNNB1 (0.34) | HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL30566393 | 0.81 | CTNNB1 (0.34) | HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL14070894 | 0.78 | L3MBTL1 (0.32) | HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL29735235 | 0.78 | PARP1 (0.32) | HTR2AHTR2CHTR2B | |
| SCHEMBL23087749 | 0.78 | PARP1 (0.32) | HTR2AHTR2CHTR2B | |
| SCHEMBL25166676 | 0.78 | HTR2A (0.32) | HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL14079586 | 0.75 | HTR2A (0.30) | HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL14070904 | 0.75 | HTR2A (0.30) | HTR2AHTR2CHTR2BHTR1AKCNH2 | |
| SCHEMBL14079585 | 0.75 | KCNH2 (0.37) | HTR2AHTR2CHTR2BHTR1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021220170-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-11-04 | — | — | WO | disclosed |
| US-20080020148-A1 | Chromane Derivatives Method for Production and the Use Thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020148-A1 | Chromane Derivatives Method for Production and the Use Thereof | C1S, CHRM1, C1R | HTR2A 703/4885HTR2C 713/4885HTR2B 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.